<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05047952</url>
  </required_header>
  <id_info>
    <org_study_id>BCDF002</org_study_id>
    <nct_id>NCT05047952</nct_id>
  </id_info>
  <brief_title>Vortioxetine for Post-Covid-19 Syndrome</brief_title>
  <official_title>Randomized, Double-Blinded, Placebo-Controlled Study Evaluating Vortioxetine for Cognitive Deficits in Persons With Post-COVID-19 Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brain and Cognition Discovery Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brain and Cognition Discovery Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blinded, placebo-controlled trial will be conducted to evaluate&#xD;
      vortioxetine, an antidepressant with established pro-cognitive properties, for the treatment&#xD;
      of cognitive deficits which develop during or after an infection consistent with COVID-19,&#xD;
      continue for more than 12 weeks and are not explained by an alternative diagnosis (i.e.,&#xD;
      post-COVID-19 syndrome). Participants will receive vortioxetine (10-20 mg) or placebo for 8&#xD;
      weeks. Changes in cognitive functioning from baseline to endpoint (week 8) will be assessed&#xD;
      via the Digit Symbol Substitution Test (DSST).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 10-30% of individuals who have recovered from acute COVID-19 infection present&#xD;
      with unabating, non-specific, distressing, and functionally impairing symptoms (i.e.,&#xD;
      post-COVID-19 syndrome), including, but are not limited to, cognitive impairment (e.g.,&#xD;
      &quot;brain fog&quot;), fatigue, apathy, depression, anxiety, and insomnia. Although a consensus&#xD;
      definition of post-COVID-19 syndrome does not currently exist, the UK National Institutes for&#xD;
      Health and Care Excellence (NICE) have proposed a working definition of 'post-COVID-19&#xD;
      syndrome', characterized as a collection of symptoms which develop during or following&#xD;
      COVID-19 infection, persist for more than 12 weeks, and are not sufficiently explained by&#xD;
      alternative diagnoses.&#xD;
&#xD;
      Consensus exists that the phenomenology of post-COVID-19 syndrome is subserved by disturbance&#xD;
      in immune-inflammatory systems. In addition, a candidate treatment for post-COVID-19 syndrome&#xD;
      should be capable of improving measures of cognitive function (i.e., objective and&#xD;
      subjective), motivation and energy, as well as reducing fatigue, as multiple studies report&#xD;
      that the foregoing symptoms are some of the most common and debilitating features of&#xD;
      post-COVID-19 syndrome.&#xD;
&#xD;
      Vortioxetine is established as pro-cognitive, is documented to improve anticipatory and&#xD;
      consummatory measures of reward function/anhedonia, and has demonstrated significant&#xD;
      improvement on measures of motivation and energy. Moreover, vortioxetine is not associated&#xD;
      with emotional blunting and has preliminary evidence of improving sleep behaviour and&#xD;
      circadian rhythms. The candidacy of vortioxetine as an effective treatment for post-COVID-19&#xD;
      syndrome is further strengthened by evidence indicating that vortioxetine exerts modulatory&#xD;
      effects on cellular and cytokine systems known to be activated in persons with post-COVID-19&#xD;
      syndrome.&#xD;
&#xD;
      Vortioxetine (10-20 mg) may be an effective treatment for cognitive impairment in persons&#xD;
      with post-COVID-19 syndrome. An 8-week randomized, double-blinded, placebo-controlled&#xD;
      clinical trial will be conducted to determine efficacy and safety for this indication against&#xD;
      placebo. Changes in cognitive functioning from baseline to endpoint (week 8) will be assessed&#xD;
      via the Digit Symbol Substitution Test (DSST).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 16, 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Digit Symbol Substitution Test (DSST)</measure>
    <time_frame>Weeks 0-8</time_frame>
    <description>Baseline-to-endpoint (i.e., Week 8) change in the Digit Symbol Substitution Test (DSST) will be used to assess change in cognitive function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Trails Making Test (TMT)-A/B</measure>
    <time_frame>Weeks 0-8</time_frame>
    <description>Baseline-to-endpoint (i.e., Week 8) change in the Trails Making Test (TMT)-A/B will be used to assess change in cognitive function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rey's auditory verbal learning test (RAVLT)</measure>
    <time_frame>Weeks 0-8</time_frame>
    <description>Baseline-to-endpoint (i.e., Week 8) change in the Rey's auditory verbal learning test (RAVLT) will be used to assess change in verbal memory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceived Deficits Questionnaire, 20-item (PDQ-20)</measure>
    <time_frame>Weeks 0-8</time_frame>
    <description>Baseline-to-endpoint (i.e., Week 8) change in Perceived Deficits Questionnaire, 20-item (PDQ-20) will be used to assess change in subjective cognitive functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue Severity Scale (FSS)</measure>
    <time_frame>Weeks 0-8</time_frame>
    <description>Baseline-to-endpoint (i.e., Week 8) change in the Fatigue Severity Scale (FSS) will be used to assess change in severity and impact of fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Snaith Hamilton Pleasure Rating Scale (SHAPS)</measure>
    <time_frame>Weeks 0-8</time_frame>
    <description>Baseline-to-endpoint (i.e., Week 8) change in the Snaith Hamilton Pleasure Rating Scale (SHAPS) will be used to assess change in four domains of pleasure response/hedonic experience: interest/pastimes, social interaction, sensory experience, and food/drink.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Health Questionnaire, 9-item (PHQ-9)</measure>
    <time_frame>Weeks 0-8</time_frame>
    <description>Baseline-to-endpoint (i.e., Week 8) change in the Patient Health Questionnaire, 9-item (PHQ-9) will be used to assess change across self-rated depressive symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Generalized Anxiety Scale, 7-item (GAD-7)</measure>
    <time_frame>Weeks 0-8</time_frame>
    <description>Baseline-to-endpoint (i.e., Week 8) change in the Generalized Anxiety Scale, 7-item (GAD-7) will be used to assess change across self-rated general anxiety symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>World Health Organization Wellbeing Scale, 5-item (WHO-5)</measure>
    <time_frame>Weeks 0-8</time_frame>
    <description>Baseline-to-endpoint (i.e., Week 8) change in the World Health Organization Wellbeing Scale, 5-item (WHO-5) will be used to assess change in subjective well-being.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQol, 5-dimension, 5-level (EQ-5D-5L)</measure>
    <time_frame>Weeks 0-8</time_frame>
    <description>Baseline-to-endpoint (i.e., Week 8) change in the EuroQol, 5-dimension, 5-level (EQ-5D-5L) will be used to assess change in quality of daily life across 5 dimensions (mobility, capacity for self-care, conduct of usual activities, pain/discomfort and anxiety/depression).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sheehan Disability Scale (SDS)</measure>
    <time_frame>Weeks 0-8</time_frame>
    <description>Baseline-to-endpoint (i.e., Week 8) change in the Sheehan Disability Scale (SDS) will be used to assess change in functional impairment due to disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-Covid Functional Scale (PCFS)</measure>
    <time_frame>Weeks 0-8</time_frame>
    <description>Baseline-to-endpoint (i.e., Week 8) change in the Post-Covid Functional Scale (PCFS) will be used to assess change in functional status over time following COVID-19 infection.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Post-COVID-19 Syndrome</condition>
  <condition>Cognitive Impairment</condition>
  <condition>Fatigue</condition>
  <arm_group>
    <arm_group_label>Vortioxetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Start at 10 mg vortioxetine once daily (OD) for the first 2 weeks, then dosed up to 20 mg vortioxetine OD for weeks 2-8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsule taken OD for weeks 0-8.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vortioxetine</intervention_name>
    <description>Participants receiving vortioxetine will be provided 10 mg/day on days 1-14 of the treatment period, and will be titrated to 20 mg/day at the start of week 3 (day 15) based on study clinician judgment. For the remaining 6 weeks, the dose of vortioxetine will be 20 mg/day, unless adjudicated otherwise by a study clinician.</description>
    <arm_group_label>Vortioxetine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A placebo pill will be taken once daily.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-65&#xD;
&#xD;
          -  Meets NICE-defined post-COVID-19 syndrome (NICE Definition: Signs and symptoms that&#xD;
             develop during or after an infection consistent with COVID-19, continue for more than&#xD;
             12 weeks and are not explained by an alternative diagnosis). To ensure the above&#xD;
             criteria is met, participants will only be included in the study if they meet all&#xD;
             eligibility criteria more than 12 weeks from their confirmed and documented positive&#xD;
             polymerase chain reaction (PCR) SARS-CoV-2 test.&#xD;
&#xD;
          -  Documented history of SARS-CoV-2 infection with typical symptoms, and requiring&#xD;
             positive SARS-CoV-2 test (PCR, antigen or antibody) at some point during the course or&#xD;
             (in the case of antibodies) also after the acute course of illness&#xD;
&#xD;
          -  Subjective cognitive complaints as detected by the Perceived Deficits Questionnaire&#xD;
             (PDQ)-5&#xD;
&#xD;
          -  Ability to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current symptoms are fully explained by major depressive disorder or bipolar disorder.&#xD;
&#xD;
          -  Pre-existing conditions that may cause cognitive impairment, or symptoms similar to&#xD;
             those seen in post-COVID-19 syndrome (e.g., major neurocognitive disorder,&#xD;
             schizophrenia, chronic fatigue syndrome [CFS]/ encephalitis meningitis [EM]), as&#xD;
             assessed by Mini International Neuropsychiatric Interview (MINI) 7.0.2.&#xD;
&#xD;
          -  Inability to follow study procedures.&#xD;
&#xD;
          -  Known intolerance to vortioxetine and/or prior trial of vortioxetine with demonstrated&#xD;
             inefficacy.&#xD;
&#xD;
          -  Not currently taking any other antidepressant in the past 4 weeks.&#xD;
&#xD;
          -  Current alcohol or substance use disorder.&#xD;
&#xD;
          -  Inability to provide consent.&#xD;
&#xD;
          -  Current alcohol and/or substance use disorder as confirmed by the M.I.N.I 7.0.2&#xD;
&#xD;
          -  Presence of comorbid psychiatric disorder that is a primary focus of clinical concern&#xD;
             as confirmed by the M.I.N.I. 7.0.2.&#xD;
&#xD;
          -  Medications approved and/or employed off-label for cognitive dysfunction (e.g.,&#xD;
             psychostimulants).&#xD;
&#xD;
          -  Any medication for a general medical disorder that, in the opinion of the&#xD;
             investigator, may affect cognitive function.&#xD;
&#xD;
          -  Use of benzodiazepines within 12 hours of cognitive assessments.&#xD;
&#xD;
          -  Consumption of alcohol within 8 hours of cognitive assessments.&#xD;
&#xD;
          -  Physical, cognitive, or language impairments sufficient to adversely affect data&#xD;
             derived from cognitive assessments.&#xD;
&#xD;
          -  Diagnosed reading disability or dyslexia.&#xD;
&#xD;
          -  Clinically significant learning disorder by history.&#xD;
&#xD;
          -  Electroconvulsive therapy (ECT) in the last 6 months.&#xD;
&#xD;
          -  History of moderate or severe head trauma (e.g., loss of consciousness for &gt;1 hour),&#xD;
             other neurological disorders, or unstable systemic medical diseases that in the&#xD;
             opinion of the investigator are likely to affect the central nervous system.&#xD;
&#xD;
          -  Pregnant and/or breastfeeding.&#xD;
&#xD;
          -  Received investigational agents as part of a separate study within 30 days of the&#xD;
             screening visit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger S. McIntyre, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brain and Cognition Discovery Foundation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roger S. McIntyre, MD</last_name>
    <phone>416-943-6284</phone>
    <email>roger.mcintyre@uhn.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mehala Subramaniapillai, MSc</last_name>
    <email>m.subram@mail.utoronto.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Canadian Rapid Treatment Centre of Excellence (CRTCE)</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5G 3H4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roger McIntyre</last_name>
      <phone>416- 943-6284</phone>
      <email>roger.mcintyre@uhn.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>https://covid19.who.int</url>
    <description>World Health Organization (WHO) COVID-19 Dashboard</description>
  </link>
  <link>
    <url>https://www.nice.org.uk/guidance/ng188</url>
    <description>National Institute for Health and Care Excellence (NICE) COVID-19 rapid guideline: managing the long-term effects of COVID-19</description>
  </link>
  <link>
    <url>https://www.bsrm.org.uk/downloads/covid-19bsrmissue1-published-27-4-2020.pdf</url>
    <description>Rehabilitation in the wake of Covid-19 - A phoenix from the ashes; British Society of Rehabilitation Medicine (BSRM)</description>
  </link>
  <link>
    <url>https://patientresearchcovid19.com/research/report-1/</url>
    <description>An Analysis of the Prolonged COVID-19 Symptoms Survey by Patient-Led Research Team</description>
  </link>
  <link>
    <url>https://www.medrxiv.org/content/10.1101/2020.12.24.20248802v3</url>
    <description>Characterizing Long COVID in an International Cohort: 7 Months of Symptoms and Their Impact Hannah E. Davis, Gina S. Assaf, Lisa McCorkell, Hannah Wei, Ryan J. Low, Yochai Re'em, Signe Redfield, Jared P. Austin, Athena Akrami medRxiv 2020.12.24.20248802;</description>
  </link>
  <link>
    <url>https://clinicaltrials.gov/ct2/show/NCT03835715</url>
    <description>Study With Vortioxetine on Emotional Functioning in Patients With Depression (COMPLETE)</description>
  </link>
  <reference>
    <citation>Mahase E. Covid-19: What do we know about &quot;long covid&quot;? BMJ. 2020 Jul 14;370:m2815. doi: 10.1136/bmj.m2815.</citation>
    <PMID>32665317</PMID>
  </reference>
  <reference>
    <citation>Burke MJ, Del Rio C. Long COVID has exposed medicine's blind-spot. Lancet Infect Dis. 2021 Aug;21(8):1062-1064. doi: 10.1016/S1473-3099(21)00333-9. Epub 2021 Jun 18.</citation>
    <PMID>34153235</PMID>
  </reference>
  <reference>
    <citation>Carfì A, Bernabei R, Landi F; Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent Symptoms in Patients After Acute COVID-19. JAMA. 2020 Aug 11;324(6):603-605. doi: 10.1001/jama.2020.12603.</citation>
    <PMID>32644129</PMID>
  </reference>
  <reference>
    <citation>Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, Pujol JC, Klaser K, Antonelli M, Canas LS, Molteni E, Modat M, Jorge Cardoso M, May A, Ganesh S, Davies R, Nguyen LH, Drew DA, Astley CM, Joshi AD, Merino J, Tsereteli N, Fall T, Gomez MF, Duncan EL, Menni C, Williams FMK, Franks PW, Chan AT, Wolf J, Ourselin S, Spector T, Steves CJ. Attributes and predictors of long COVID. Nat Med. 2021 Apr;27(4):626-631. doi: 10.1038/s41591-021-01292-y. Epub 2021 Mar 10. Erratum in: Nat Med. 2021 Jun;27(6):1116.</citation>
    <PMID>33692530</PMID>
  </reference>
  <reference>
    <citation>Mahase E. Long covid could be four different syndromes, review suggests. BMJ. 2020 Oct 14;371:m3981. doi: 10.1136/bmj.m3981.</citation>
    <PMID>33055076</PMID>
  </reference>
  <reference>
    <citation>Puntmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, Hoffmann J, Shchendrygina A, Escher F, Vasa-Nicotera M, Zeiher AM, Vehreschild M, Nagel E. Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020 Nov 1;5(11):1265-1273. doi: 10.1001/jamacardio.2020.3557. Erratum in: JAMA Cardiol. 2020 Nov 1;5(11):1308.</citation>
    <PMID>32730619</PMID>
  </reference>
  <reference>
    <citation>Lenze EJ, Mattar C, Zorumski CF, Stevens A, Schweiger J, Nicol GE, Miller JP, Yang L, Yingling M, Avidan MS, Reiersen AM. Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial. JAMA. 2020 Dec 8;324(22):2292-2300. doi: 10.1001/jama.2020.22760.</citation>
    <PMID>33180097</PMID>
  </reference>
  <reference>
    <citation>Hoertel N, Sánchez-Rico M, Vernet R, Beeker N, Jannot AS, Neuraz A, Salamanca E, Paris N, Daniel C, Gramfort A, Lemaitre G, Bernaux M, Bellamine A, Lemogne C, Airagnes G, Burgun A, Limosin F; AP-HP / Universities / INSERM COVID-19 Research Collaboration and AP-HP COVID CDR Initiative. Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study. Mol Psychiatry. 2021 Feb 4. doi: 10.1038/s41380-021-01021-4. [Epub ahead of print]</citation>
    <PMID>33536545</PMID>
  </reference>
  <reference>
    <citation>Christensen MC, Loft H, McIntyre RS. Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: A novel dual outcome measure in depressive disorders. J Affect Disord. 2018 Feb;227:787-794. doi: 10.1016/j.jad.2017.11.081. Epub 2017 Nov 16.</citation>
    <PMID>29689693</PMID>
  </reference>
  <reference>
    <citation>McIntyre RS, Florea I, Tonnoir B, Loft H, Lam RW, Christensen MC. Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder. J Clin Psychiatry. 2017 Jan;78(1):115-121. doi: 10.4088/JCP.16m10744.</citation>
    <PMID>27780334</PMID>
  </reference>
  <reference>
    <citation>McIntyre RS, Harrison J, Loft H, Jacobson W, Olsen CK. The Effects of Vortioxetine on Cognitive Function in Patients with Major Depressive Disorder: A Meta-Analysis of Three Randomized Controlled Trials. Int J Neuropsychopharmacol. 2016 Jun 15;19(10). pii: pyw055. doi: 10.1093/ijnp/pyw055.</citation>
    <PMID>27312740</PMID>
  </reference>
  <reference>
    <citation>Cao B, Park C, Subramaniapillai M, Lee Y, Iacobucci M, Mansur RB, Zuckerman H, Phan L, McIntyre RS. The Efficacy of Vortioxetine on Anhedonia in Patients With Major Depressive Disorder. Front Psychiatry. 2019 Jan 31;10:17. doi: 10.3389/fpsyt.2019.00017. eCollection 2019.</citation>
    <PMID>30766492</PMID>
  </reference>
  <reference>
    <citation>Subramaniapillai M, Mansur RB, Zuckerman H, Park C, Lee Y, Iacobucci M, Cao B, Ho R, Lin K, Phan L, McIntyre RS. Association between cognitive function and performance on effort based decision making in patients with major depressive disorder treated with Vortioxetine. Compr Psychiatry. 2019 Oct;94:152113. doi: 10.1016/j.comppsych.2019.07.006. Epub 2019 Jul 24.</citation>
    <PMID>31404802</PMID>
  </reference>
  <reference>
    <citation>Fagiolini A, Florea I, Loft H, Christensen MC. Effectiveness of Vortioxetine on Emotional Blunting in Patients with Major Depressive Disorder with inadequate response to SSRI/SNRI treatment. J Affect Disord. 2021 Mar 15;283:472-479. doi: 10.1016/j.jad.2020.11.106. Epub 2020 Nov 19.</citation>
    <PMID>33516560</PMID>
  </reference>
  <reference>
    <citation>Cao B, Park C, Rosenblat JD, Chen Y, Iacobucci M, Subramaniapillai M, Mansur RB, Zuckerman H, Lee Y, McIntyre RS. Changes in sleep predict changes in depressive symptoms in depressed subjects receiving vortioxetine: An open-label clinical trial. J Psychopharmacol. 2019 Nov;33(11):1388-1394. doi: 10.1177/0269881119874485. Epub 2019 Sep 18.</citation>
    <PMID>31530216</PMID>
  </reference>
  <reference>
    <citation>Talmon M, Rossi S, Pastore A, Cattaneo CI, Brunelleschi S, Fresu LG. Vortioxetine exerts anti-inflammatory and immunomodulatory effects on human monocytes/macrophages. Br J Pharmacol. 2018 Jan;175(1):113-124. doi: 10.1111/bph.14074. Epub 2017 Nov 28.</citation>
    <PMID>29057467</PMID>
  </reference>
  <reference>
    <citation>Tomaz VS, Chaves Filho AJM, Cordeiro RC, Jucá PM, Soares MVR, Barroso PN, Cristino LMF, Jiang W, Teixeira AL, de Lucena DF, Macedo DS. Antidepressants of different classes cause distinct behavioral and brain pro- and anti-inflammatory changes in mice submitted to an inflammatory model of depression. J Affect Disord. 2020 May 1;268:188-200. doi: 10.1016/j.jad.2020.03.022. Epub 2020 Mar 6.</citation>
    <PMID>32174477</PMID>
  </reference>
  <reference>
    <citation>Mahableshwarkar AR, Zajecka J, Jacobson W, Chen Y, Keefe RS. A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder. Neuropsychopharmacology. 2015 Jul;40(8):2025-37. doi: 10.1038/npp.2015.52. Epub 2015 Feb 17. Erratum in: Neuropsychopharmacology. 2016 Nov;41(12 ):2961.</citation>
    <PMID>25687662</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 12, 2021</study_first_submitted>
  <study_first_submitted_qc>September 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2021</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vortioxetine</keyword>
  <keyword>fatigue</keyword>
  <keyword>long COVID</keyword>
  <keyword>post-acute COVID syndrome</keyword>
  <keyword>long haul COVID</keyword>
  <keyword>brain fog</keyword>
  <keyword>cognitive deficit</keyword>
  <keyword>cognitive dysfunction</keyword>
  <keyword>COVID-19 sequelae</keyword>
  <keyword>post-acute COVID-19 syndrome</keyword>
  <keyword>Trintellix</keyword>
  <keyword>chronic COVID syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vortioxetine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

